# Burosumab

Source: https://onco.cc/drugs/burosumab/  
OnCo record `burosumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Crysvita is an antibody for a rare bone-softening condition in which the body leaks phosphate. Some small tumours cause it by making too much of a hormone called FGF23; when the tumour cannot be found or removed, Crysvita blocks the hormone.

## Summary

Burosumab (Crysvita) has been authorised in the EU since 19 February 2018 (CHMP opinion 14 December 2017; marketing authorisation holder Kyowa Kirin Holdings B.V.; orphan designation) for X-linked hypophosphataemia in children and adolescents aged 1 to 17 with radiographic bone disease and in adults, and for FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised. The cancer-care indication is the second: it treats the metabolic effect of a tumour rather than the tumour itself.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-22
- Also known as: burosumab; Crysvita; KRN23
- Tags: ema-register; supportive
- Brand: Crysvita
- Modality: Monoclonal antibody (anti-FGF23)
- Mechanism: Antibody to fibroblast growth factor 23; used for FGF23-related hypophosphataemia, including the form caused by phosphate-wasting tumours (tumour-induced osteomalacia), where the tumour cannot be found or removed (indication wording, EMA).
- Approvals: EU 2018: X-linked hypophosphataemia; FGF23-related hypophosphataemia in tumour-induced osteomalacia (phosphaturic mesenchymal tumours not curatively resectable or localisable)

## Sources

- EMA: Crysvita (EPAR): https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita

## Connected records

- companies: [Kyowa Kirin](https://onco.cc/companies/kyowa-kirin/)

---
JSON: https://onco.cc/api/v1/entities/burosumab.json